Previous Close | 9.93 |
Open | 9.93 |
Bid | 0.00 x 2200 |
Ask | 9.93 x 1800 |
Day's Range | 9.92 - 9.93 |
52 Week Range | 9.66 - 10.40 |
Volume | |
Avg. Volume | 14,614 |
Market Cap | 176.09M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | 62.00 |
EPS (TTM) | 0.16 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
NAARDEN, Netherlands & MENLO PARK, Calif., July 25, 2022--NewAmsterdam Pharma Holding B.V. ("Company"), a late clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, and Frazier Lifesciences Acquisition Corporation ("FLAC"), a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners, today announced that they have entered into a definitive business combination agreement. Upon closing
The big shareholder groups in Frazier Lifesciences Acquisition Corporation ( NASDAQ:FLAC ) have power over the company...
A look at the shareholders of Frazier Lifesciences Acquisition Corporation ( NASDAQ:FLAC ) can tell us which group is...